Corrigendum to “The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2021;100:225–237
Authors: Gema Ariceta, Bradley P. Dixon, Seong Heon Kim, Gaurav Kapur, Teri Mauch, Stephan Ortiz, Marc Vallee, Andrew E. Denker, Hee Gyung Kang, Larry A. Greenbaum, Helen Lovell, Melissa Muff-Luett, Kristin Malone, Oluwasegun Adeagbo, Alexandria Wilkerson, Gloria Fraga, Scherezade Sarri, Hae Il Cheong, Yo Han Ahn, Kyoung Hee Han, Elke Wühl, Gianluigi Ardissino, Valentina Capone, Alexandru Constantinescu, Ivy Boydstun, Reem Raafat, Marezhe Mersha, Belkis Wandique-Rapalo, Hiroshi Hataya, None Hamada, None Terano, Lesley Rees, Araceli Garcia Pose, Inés Vergara Pérez, Mercedes Cao Vilariño, Brigitte Adams, Tram Nathalie
Journal: Kidney International (2023)

DOI of original article: https://doi.org/10.1016/j.kint.2020.10.046 The authors regret that the minimum age at time of first infusion value was reported incorrectly. The original reported age at time of first infusion, median (range), years, was 5.2 (0.5–17.3). The correct age at time of first infusion, median (range), years, is 5.2 (0.9–17.3). These errors have been corrected in the original article online. The authors would like to apologize for any inconvenience caused. Helen Lovell (University of Nebraska Medical Center, Nebraska, USA), Melissa Muff-Luett (University of Nebraska Medical Center, Nebraska, USA), Kristin Malone (University of Nebraska Medical Center, Nebraska, USA), Oluwasegun Adeagbo (Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA), Alexandria Wilkerson (Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA), Gloria Fraga (University Hospital Vall d'Hebron, Barcelona, Spain), Scherezade Sarri (University Hospital Vall d'Hebron, Barcelona, Spain), Hae Il Cheong (Division of Pediatric Nephrology, Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea), Yo Han Ahn (Division of Pediatric Nephrology, Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea), Kyoung Hee Han (Jeju National University, School of Medicine, Korea), Elke Wühl (University Hospital Heidelberg for Pediatric and Adolescent Medicine, Heidelberg, Germany), Gianluigi Ardissino (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy), Valentina Capone (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy), Alexandru Constantinescu (Joe DiMaggio Children's Hospital, Hollywood, Florida, USA), Ivy Boydstun (Joe DiMaggio Children's Hospital, Hollywood, Florida, USA), Reem Raafat (Joe DiMaggio Children's Hospital, Hollywood, Florida, USA), Marezhe Mersha (Joe DiMaggio Children's Hospital, Hollywood, Florida, USA), Belkis Wandique-Rapalo (Joe DiMaggio Children's Hospital, Hollywood, Florida, USA), Hiroshi Hataya (Tokyo Metropolitan Children's Medical Center, Tokyo, Japan), Dr. Hamada (Tokyo Metropolitan Children's Medical Center, Tokyo, Japan), Dr. Terano (Tokyo Metropolitan Children's Medical Center, Tokyo, Japan), Lesley Rees (Great Ormond Street Hospital, London, UK), Araceli Garcia Pose (Hospital Universitario Infanta Sofía, Madrid, Spain), Inés Vergara Pérez (Hospital Universitario Infanta Sofía, Madrid, Spain), Mercedes Cao Vilariño (Hospital Universitario Infanta Sofía, Madrid, Spain), Brigitte Adams (Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium), and Tram Nathalie (Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium). The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatmentKidney InternationalVol. 100Issue 1PreviewRavulizumab, a long-acting complement C5 inhibitor engineered from eculizumab, allows extending maintenance dosing from every 2–3 weeks to every 4–8 weeks depending on bodyweight. Here, we evaluated the efficacy and safety of ravulizumab in complement inhibitor-naïve children (under 18 years) with atypical hemolytic uremic syndrome. In this phase III, single-arm trial, ravulizumab was administered every eight weeks in patients 20 kg and over, and four weeks in patients under 20 kg. The primary endpoint was a complete thrombotic microangiopathy response (normalization of platelet count and lactate dehydrogenase, and a 25% or more improvement in serum creatinine) through 26 weeks. Full-Text PDF Open Access